ProPhase Labs (PRPH) FDA Approvals $0.01 0.00 (-16.89%) As of 09/18/2026 03:51 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings ProPhase Labs' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by ProPhase Labs (PRPH). Over the past two years, ProPhase Labs has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as BE-Smart. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. BE-Smart FDA Regulatory Events BE-Smart is a drug developed by ProPhase Labs for the following indication: esophageal cancer test. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Clinical Study - October 22,2025Clinical Study Drug: BE-SmartAnnounced Date: October 22, 2025Indication: esophageal cancer testAnnouncementProPhase Labs Inc. announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.AI SummaryProPhase Labs announced that its pivotal clinical study by Hartley et al. (2025), validating the BE-Smart™ esophageal cancer test, has been accepted for publication in Clinical Gastroenterology and Hepatology. The study shows BE-Smart achieved 100% sensitivity in detecting patients who later developed cancer and demonstrated strong predictive accuracy with an AUC up to 1.0. BE-Smart is an eight-protein, mass-spectrometry assay that stratifies the risk of progression from Barrett’s Esophagus to high-grade dysplasia or esophageal adenocarcinoma. With millions of endoscopies performed annually for GERD and Barrett’s surveillance, the test targets a multibillion-dollar market. ProPhase is advancing regulatory filings, scaling its laboratory operations and partnering with leading gastroenterology practices. A phased commercial rollout is planned for 2026, allowing physicians to order BE-Smart through standard pathology channels. This milestone sets the stage for revenue growth and wider access to advanced molecular screening.Read Announcement ProPhase Labs FDA Events - Frequently Asked Questions Has ProPhase Labs received FDA approval? As of now, ProPhase Labs (PRPH) has not received any FDA approvals for its therapy in the last two years. What drugs has ProPhase Labs submitted to the FDA? In the past two years, ProPhase Labs (PRPH) has reported FDA regulatory activity for BE-Smart. What is the most recent FDA event for ProPhase Labs? The most recent FDA-related event for ProPhase Labs occurred on October 22, 2025, involving BE-Smart. The update was categorized as "Clinical Study," with the company reporting: "ProPhase Labs Inc. announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association." What conditions do ProPhase Labs' current drugs treat? Currently, ProPhase Labs has one therapy (BE-Smart) targeting the following condition: esophageal cancer test. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AbCellera Biologics FDA EventsAquestive Therapeutics FDA EventsHemab Therapeutics FDA EventsAdherex Technologies FDA EventsMIRA Pharmaceuticals FDA EventsNeuroOne Medical Technologies FDA EventsQuince Therapeutics FDA EventsSol-Gel Technologies FDA EventsAbbVie FDA EventsBristol Myers Squibb FDA EventsNuvation Bio FDA EventsAbeona Therapeutics FDA EventsArtelo Biosciences FDA EventsBiogen FDA EventsFate Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies PainReform FDA Events Aditxt FDA Events Fortress Biotech FDA Events Neonc Technologies FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:PRPH last updated on 10/22/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clinical Study - October 22,2025Clinical Study Drug: BE-SmartAnnounced Date: October 22, 2025Indication: esophageal cancer testAnnouncementProPhase Labs Inc. announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.AI SummaryProPhase Labs announced that its pivotal clinical study by Hartley et al. (2025), validating the BE-Smart™ esophageal cancer test, has been accepted for publication in Clinical Gastroenterology and Hepatology. The study shows BE-Smart achieved 100% sensitivity in detecting patients who later developed cancer and demonstrated strong predictive accuracy with an AUC up to 1.0. BE-Smart is an eight-protein, mass-spectrometry assay that stratifies the risk of progression from Barrett’s Esophagus to high-grade dysplasia or esophageal adenocarcinoma. With millions of endoscopies performed annually for GERD and Barrett’s surveillance, the test targets a multibillion-dollar market. ProPhase is advancing regulatory filings, scaling its laboratory operations and partnering with leading gastroenterology practices. A phased commercial rollout is planned for 2026, allowing physicians to order BE-Smart through standard pathology channels. This milestone sets the stage for revenue growth and wider access to advanced molecular screening.Read Announcement
Free PRPH Stock Alerts